Identifying the Riemann zeros by periodically driving a single qubit

The Riemann hypothesis, one of the most important open problems in pure mathematics, implies the most profound secret of prime numbers. One of the most interesting approaches to solve this hypothesis is to connect the problem with the spectrum of the physical Hamiltonian of a quantum system. However, none of the proposed quantum Hamiltonians have been experimentally feasible.Here, we report the first experiment to identify the first non-trivial zeros of the Riemann zeta function and the first two zeros of P\'olya's fake zeta function, using a novel Floquet method, through properly designed periodically driving functions. According to this method, the zeros of these functions are characterized by the occurrence of crossings of quasi-energies when the dynamics of the system are frozen. The experimentally obtained zeros are in excellent agreement with their exact values. Our study provides the first experimental realization of the Riemann zeros, which may provide new insights into this fundamental mathematical problem.Comment: 5 pages, 7 figure

Modeling of Cloud-Based Digital Twins for Smart Manufacturing with MT Connect

The common modeling of digital twins uses an information model to describe the physical machines. The integration of digital twins into productive cyber-physical cloud manufacturing (CPCM) systems imposes strong demands such as reducing overhead and saving resources. In this paper, we develop and investigate a new method for building cloud-based digital twins (CBDT), which can be adapted to the CPCM platform. Our method helps reduce computing resources in the information processing center for efficient interactions between human users and physical machines. We introduce a knowledge resource center (KRC) built on a cloud server for information intensive applications. An information model for one type of 3D printers is designed and integrated into the core of the KRC as a shared resource. Several experiments are conducted and the results show that the CBDT has an excellent performance compared to existing methods

Effect of weaning age on growth performance, feed efficiency, nutrient digestibility and blood-biochemical parameters in Droughtmaster crossbred beef calves

Objective The objective of this study was to determine the effect of weaning age on intake, performance, nutrition metabolism and serum parameters of beef calves. Methods Sixty Droughtmaster crossbred calves were assigned to 5 groups with 12 calves in each group. The calves in control group remained with the dams till the 22-week age, while the calves weaned at 28 d (4 wk), 42 d (6 wk), 56 d (8 wk), and 70 d (10 wk) of age were sent to group 4 wk, group 6 wk, group 8 wk, and group 10 wk, respectively, and then were fed on milk replacer till the 22-week age. Feed intake and body weight and size were record and blood metabolites were measured. And 24 calves of them (6 in each group) were picked randomly for digestion and metabolism trail. Feed, feces and urine sample were taken and measured. Results Dry matter intake of calves in group 4 wk was significantly lower than those in the remaining groups from wk 17 to 22 (p0.05) but was higher than that of group 4 wk (p<0.05). Calves in group 6 wk had higher final body weight and total gain than group 4 wk, but no difference of total gain with that of groups 8 wk, 10 wk, and control group. And weaning calves at 6-week age brought higher feed efficiency and average daily gain from wk 14 to wk 22, and higher dry matter and organic matter digestibility at 21 wk. Conclusion It is concluded that the weaning of calves at 6 weeks of age gave positive results

An animal model of SARS produced by infection of Macaca mulatta with SARS coronavirus.

A new SARS animal model was established by inoculating SARS coronavirus (SARS-CoV) into rhesus macaques (Macaca mulatta) through the nasal cavity. Pathological pulmonary changes were successively detected on days 5-60 after virus inoculation. All eight animals showed a transient fever 2-3 days after inoculation. Immunological, molecular biological, and pathological studies support the establishment of this SARS animal model. Firstly, SARS-CoV-specific IgGs were detected in the sera of macaques from 11 to 60 days after inoculation. Secondly, SARS-CoV RNA could be detected in pharyngeal swab samples using nested RT-PCR in all infected animals from 5 days after virus inoculation. Finally, histopathological changes of interstitial pneumonia were found in the lungs during the 60 days after viral inoculation: these changes were less marked at later time points, indicating that an active healing process together with resolution of an acute inflammatory response was taking place in these animals. This animal model should provide insight into the mechanisms of SARS-CoV-related pulmonary disease and greatly facilitate the development of vaccines and therapeutics against SARS

Trial sequential analysis and updated meta-analysis of fluvoxamine on clinical deterioration in adult patients with symptomatic COVID-19 infection

Preliminary meta-analyses suggested that fluvoxamine was effective in treating COVID-19 infection. However, the reliability of this evidence has not yet been examined. MEDLINE, CENTRAL, EMBASE, PsycINFO, and ClinicalTrials.gov were searched to identify any randomized controlled trials (RCTs) from the inception of the databases to 5 February 2023. We used trial sequential analysis (TSA) to examine the reliability of the current existing evidence on the benefits of fluvoxamine on COVID-19 infection. The primary outcome was clinical deterioration, as defined in the original study (reported as odds ratio (OR), with 95% confidence intervals), and the secondary outcome was hospitalization. In the TSA, we used the relative risk reduction thresholds of 10, 20, and 30%. The updated meta-analysis of the five RCTs showed that fluvoxamine was not associated with lower odds of clinical deterioration when compared with a placebo (OR: 0.81; 0.59–1.11). The effect of fluvoxamine lay within the futility boundary (i.e., lack of effect) when using a 30% relative risk reduction threshold. The effect estimates lay between the superiority and futility boundary using the 10% and 20% threshold, and the required size of information was not reached for these two thresholds. The effect of fluvoxamine on the odds of hospitalization was not statistically significant (0.76; 0.56–1.03). In conclusion, there is no reliable evidence that fluvoxamine, when compared to a placebo, reduces the relative risk of clinical deterioration among adult patients with COVID-19 infection by 30%, and a relative risk reduction of 20% or 10% is still uncertain. The role of fluvoxamine as a COVID-19 treatment cannot be justified